Third approval in China for AstraZeneca and Daiichi Sankyo’s Enhertu in less than two years
The integration of SAP S/4HANA Cloud will equip Cupid Limited with a comprehensive suite of integrated applications,
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Transaction is non-dilutive, with 100% performance-based payment through a royalty model
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Merck shared updates on the company’s oncology pipeline and focused R&D approach
Partnership to facilitate collaborative research in academia and industry to further progress in life sciences
Phase I data for tuvusertib, lead asset from the company’s unique portfolio of DDR inhibitors
225Ac-PSMA-Trillium is an investigational next-generation PSMA-targeted alpha therapy with potential to treat patients with advanced metastatic prostate cancer
Breakthrough Therapy designation for pain associated with DPN granted by FDA
Subscribe To Our Newsletter & Stay Updated
